The Psychoactive Effects of Psychiatric Medication: The Elephant in the Room

Journal of Psychoactive Drugs

Volumn 45, Issue 5, 2013, Pages 409-415

  Moncrieff, Joanna ^a   Cohen, David ^b   Porter, Sally ^c  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c SOUTH LONDON AND MAUDSLEY NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

antidepressants; antipsychotics; prescription drug dependence; psychiatric drugs; psychoactive effects; withdrawal effects

Indexed keywords

ALCOHOL; AMPHETAMINE; ANTIDEPRESSANT AGENT; BENZODIAZEPINE; CAFFEINE; LITHIUM; NEUROLEPTIC AGENT; NICOTINE; OPIATE; PSYCHEDELIC AGENT; PSYCHOTROPIC AGENT; RECREATIONAL DRUG; SEROTONIN UPTAKE INHIBITOR; VENLAFAXINE;

ARTICLE; DRUG DEPENDENCE; DSM-5; DYSPHORIA; EUPHORIA; HUMAN; NEUROPHARMACOLOGY; PSYCHOPHARMACOTHERAPY; TARDIVE DYSKINESIA; WITHDRAWAL SYNDROME;

HUMANS; MENTAL DISORDERS; PSYCHOTROPIC DRUGS; SUBSTANCE-RELATED DISORDERS;

EID: 84888071211     PISSN: 02791072     EISSN: 21599777     Source Type: Journal    
DOI: 10.1080/02791072.2013.845328     Document Type: Article

References (57)

1. Abse, D.W., Dahlstrom, W.G. and Tolley, A.G. 1960. Evaluation of tranquilizing drugs in the management of acute mental disturbance. Am J Psychiatry, 116: 973 - 980.
2. Agid, O., Kapur, S., Arenovich, T. and Zipursky, R.B. 2003. Delayed-onset hypothesis of antipsychotic action: a hypothesis tested and rejected. Arch Gen Psychiatry, 60: 1228 - 1235.
3. Awad, A.G. 1993. Subjective response to neuroleptics in schizophrenia. Schizophr Bull, 19: 609 - 618.
4. Baldessarini, R. 1985. " Drugs and the treatment of psychiatric disorders ". In The Pharmacological Basis of Therapeutics, Edited by: Gilman, A., Goodman, L., Rall, T. and Murad, F. 387 - 445. New York: Macmillan.
5. Barnhart, W.J., Makela, E.H. and Latocha, M.J. 2004. SSRI-induced apathy syndrome: a clinical review. J Psychiatr Pract, 10: 196 - 199.
6. Billioti, D.G., Begaud, B., Bazin, F., Verdoux, H., Dartigues, J.F., Peres, K., Kurth, T. and Pariente, A. 2012. Benzodiazepine use and risk of dementia: Prospective population based study. BMJ, 345: e6231
7. Bolling, M.Y. and Kohlenberg, R.J. 2004. Reasons for quitting serotonin reuptake inhibitor therapy: Paradoxical psychological side effects and patient satisfaction. Psychother Psychosom, 73: 380 - 385.
8. Bowden, C.L., Brugger, A.M., Swann, A.C., Calabrese, J.R., Janicak, P.G., Petty, F., Dilsaver, S.C., Davis, J.M., Rush, A.J. and Small, J.G. 1994. Efficacy of divalproex vs lithium and placebo in the treatment of mania: The Depakote Mania Study Group. JAMA, 271: 918 - 924.
9. Braden, W., Fink, E.B., Qualls, C.B., Ho, C.K. and Samuels, W.O. 1982. Lithium and chlorpromazine in psychotic inpatients. Psychiatry Res, 7: 69 - 81.
10. Casey, J.F., Bennett, I.F., Lindley, C.J., Hollister, L.E., Gordon, M.H. and Springer, N.N. 1960a. Drug therapy in schizophrenia: A controlled study of the relative effectiveness of chlorpromazine, promazine, phenobarbital, and placebo. Arch Gen Psychiatry, 2: 210 - 220.
11. Casey, J.F., Lasky, J.J., Klett, C.J. and Hollister, L.E. 1960b. Treatment of schizophrenic reactions with phenothiazine derivatives: A comparative study of chlorpromazine, triflupromazine, mepazine, prochlorperazine, perphenazine, and phenobarbital. Am J Psychiatry, 117: 97 - 105.
12. Cavanna, A.E., Fizzah, A., Edwards, H. and McCorry, D. 2010. Behavioural and cognitive effects of anti-epileptic drugs. Discovery Medicine, 9: 138 - 144.
13. Chouinard, G. 1988. The use of benzodiazepines in the treatment of manic-depressive illness. J Clin Psychiatry, 49: 15 - 20. Suppl
14. Cohen, D. 2007. Helping individuals withdraw from psychiatric drugs. Journal of College Student Psychotherapy, 21: 199 - 224.
15. Crane, G.E. 1956. Further studies on iproniazid phosphate. Journal of Nervous and Mental Disease, 124: 322 - 331.
16. Delay, J. and Deniker, P. 1952. 38 cas de psychoses traites par la cure prolongee et continue de 4560 R.P. C R Congres Med Alien Neurol France, 50: 503 - 513.
17. Deniker, P. 1960. Experimental neurological syndromes and the new drug therapies in psychiatry. Compr Psychiatry, 1: 92 - 102.
18. Dumont, G.J., de Visser, S.J., Cohen, A.F. and van Gerven, J.M. 2005. Biomarkers for the effects of selective serotonin reuptake inhibitors (SSRIs) in healthy subjects. Br J Clin Pharmacol, 59: 495 - 510.
19. Flugel, F. 1959. " Neuroleptic treatment in schizophrenia ". In Psychopharmacology Frontiers, Edited by: Kline, N.S. 45 - 47. Boston: Little, Brown & Co.
20. Goldsmith, L. and Moncrieff, J. 2011. The psychoactive effects of antidepressants and their association with suicidality. Curr Drug Saf, 6: 115 - 121.
21. Goudie, A.J., Smith, J.A., Robertson, A. and Cavanagh, C. 1999. Clozapine as a drug of dependence. Psychopharmacology (Berl), 142: 369 - 374.
22. Grob, C.S., Danforth, A.L., Chopra, G.S., Hagerty, M., McKay, C.R., Halberstadt, A.L. and Greer, G.R. 2011. Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. Arch Gen Psychiatry, 68: 71 - 78.
23. Herrmann, W.M. and McDonald, R.J. 1978. A multidimensional test approach for the description of the CNS activity of drugs in human pharmacology. Pharmakopsychiatr Neuropsychopharmakol, 11: 247 - 265.
24. Hindmarch, I., Kimber, S. and Cockle, S.M. 2000. Abrupt and brief discontinuation of antidepressant treatment: Effects on cognitive function and psychomotor performance. Int Clin Psychopharmacol, 15: 305 - 318.
25. Ilyas, S. and Moncrieff, J. 2012. " Trends in prescriptions and costs of drugs for mental disorders in England, 1998 to 2010 ". In British Journal of Psychiatry Vol. 200, 393 - 398.
26. Johnstone, E.C., Crow, T.J., Frith, C.D. and Owens, D.G. 1988. The Northwick Park "functional" psychosis study: Diagnosis and treatment response. Lancet, 2: 119 - 125.
27. Judah, L.N., Josephs, Z.M. and Murphree, O.D. 1961. Results of simultaneous abrupt withdrawal of ataraxics in 500 chronic psychotic patients. Am J Psychiatry, 118: 156 - 158.
28. Judd, L.L., Hubbard, B., Janowsky, D.S., Huey, L.Y. and Attewell, P.A. 1977. The effect of lithium carbonate on affect, mood, and personality of normal subjects. Arch Gen Psychiatry, 34: 346 - 351.
29. Lejoyeux, M. and Ades, J. 1997. Antidepressant discontinuation: A review of the literature. J Clin Psychiatry, 58 (Suppl 7): 11 - 15.
30. Macready, N. 2012. Opening doors of perception: Psychedelic drugs and end-of-life care. J Natl Cancer Inst, 104: 1619 - 1620.
31. Maher, A.R., Maglione, M., Bagley, S., Suttorp, M., Hu, J.H., Ewing, B., Wang, Z., Timmer, M., Sultzer, D. and Shekelle, P.G. 2011. Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults: A systematic review and meta-analysis. JAMA, 306: 1359 - 1369.
32. Mizrahi, R., Bagby, R.M., Zipursky, R.B. and Kapur, S. 2005. How antipsychotics work: The patients' perspective. Prog Neuropsychopharmacol Biol Psychiatry, 29: 859 - 864.
33. Modell, J.G. 1997. Protracted benzodiazepine withdrawal syndrome mimicking psychotic depression. Psychosomatics, 38: 160 - 161.
34. Moncrieff, J. 2001. Are antidepressants overrated? A review of methodological problems in antidepressant trials. J Nerv Ment Dis, 189: 288 - 295.
35. Moncrieff, J. 2006. Why is it so difficult to stop psychiatric drug treatment? It may be nothing to do with the original problem. Med Hypotheses, 67: 517 - 523.
36. Moncrieff, J. and Cohen, D. 2006. Do antidepressants cure or create abnormal brain states?. PLoS Med, 3: e240
37. Moncrieff, J., Cohen, D. and Mason, J.P. 2009. The subjective experience of taking antipsychotic medication: A content analysis of Internet data. Acta Psychiatr Scand, 120: 102 - 111.
38. Moncrieff, J., Wessely, S. and Hardy, R. 1998. Meta-analysis of trials comparing antidepressants with active placebos. Br J Psychiatry, 172: 227 - 231.
39. Moore, M., Yuen, H.M., Dunn, N., Mullee, M.A., Maskell, J. and Kendrick, T. 2009. Explaining the rise in antidepressant prescribing: A descriptive study using the general practice research database. BMJ, 339: b3999
40. Myslobodsky, M.S. 1993. Central determinants of attention and mood disorder in tardive dyskinesia ("tardive dysmentia"). Brain Cogn, 23: 88 - 101.
41. Newcomer, J.W. and Haupt, D.W. 2006. The metabolic effects of antipsychotic medications. Can J Psychiatry, 51: 480 - 491.
42. Prah, P., Petersen, I., Nazareth, I., Walters, K. and Osborn, D. 2012. " National changes in oral antipsychotic treatment for people with schizophrenia in primary care between 1998 and 2007 in the United Kingdom ". In Pharmacoepidemiol Drug Saf Vol. 21, 161 - 169.
43. Precourt, A., Dunewicz, M., Gregoire, G. and Williamson, D.R. 2005. Multiple complications and withdrawal syndrome associated with quetiapine/venlafaxine intoxication. Ann Pharmacother, 39: 153 - 156.
44. Prien, R.F., Caffey, E.M., Jr and Klett, C.J. 1972. Comparison of lithium carbonate and chlorpromazine in the treatment of mania: Report of the Veterans Administration and National Institute of Mental Health Collaborative Study Group. Arch Gen Psychiatry, 26: 146 - 153.
45. Rasmussen, N. 2006. Making the first amtidepressant; Amphetamine in American medicine 1929-1950. Journal of the History of Medicine and Allied Sciences, 61: 288 - 323.
46. Ray, W.A., Chung, C.P., Murray, K.T., Hall, K. and Stein, C.M. 2009. Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med, 360: 225 - 235.
47. Robertson, M.M. and Trimble, M.R. 1982. Major tranquillisers used as antidepressants: A review. J Affect Disord, 4: 173 - 193.
48. Samaha, A.N., Seeman, P., Stewart, J., Rajabi, H. and Kapur, S. 2007. "Breakthrough" dopamine supersensitivity during ongoing antipsychotic treatment leads to treatment failure over time. J Neurosci, 27: 2979 - 2986.
49. Savvas, S.M., Somogyi, A.A. and White, J.M. 2012. The effect of methadone on emotional reactivity. Addiction, 107: 388 - 392.
50. Schuckit, M.A. 1994. Alcohol and depression: A clinical perspective. Acta Psychiatr Scand Suppl, 377: 28 - 32.
51. Spitzer, R.L. 1976. More on pseudoscience in science and the case for psychiatric diagnoses: A critique of D.L. Rosenhan's "On Being Sane in Insane Places" and "The Contestual Nature of Psychiatric Diagnoses". Arch Gen Psychiatry, 33: 459 - 470.
52. Squire, L.R., Judd, L.L., Janowsky, D.S. and Huey, L.Y. 1980. Effects of lithium carbonate on memory and other cognitive functions. Am J Psychiatry, 137: 1042 - 1046.
53. Tarsy, D., Lungu, C. and Baldessarini, R.J. 2011. Epidemiology of tardive dyskinesia before and during the era of modern antipsychotic drugs. Handbook Clin Neurol, 100: 601 - 616.
54. Teal, J. 2009. Nothing personal: An empirical phenomenlogical study of the experience of 'being on an SSRI'. Journal of Phenomenological Psychology, 40: 19 - 50.
55. TREC Collaborative Group. 2003. Rapid tranquillisation for agitated patients in emergency psychiatric rooms: A randomised trial of midazolam versus haloperidol plus promethazine. BMJ, 327: 708 - 713.
56. Walsh, B.T., Seidman, S.N., Sysko, R. and Gould, M. 2002. Placebo response in studies of major depression: Variable, substantial, and growing. JAMA, 287: 1840 - 1847.
57. Wolkowitz, O.M. and Pickar, D. 1991. Benzodiazepines in the treatment of schizophrenia: A review and reappraisal. Am J Psychiatry, 148: 714 - 726.